Literature DB >> 7654857

Analysis of the p53 gene mutations in acute myelogenous leukemia: the p53 gene mutations associated with a deletion of chromosome 17.

M Kurosawa1, M Okabe, Y Kunieda, M Asaka.   

Abstract

In order to determine the relevance of the p53 tumor suppressor gene mutations in acute myelogenous leukemia (AML), we analyzed the p53 gene in genomic DNA of 18 unselected cases of AML by polymerase chain reaction-single-strand conformation polymorphism (PCR-SSCP) and direct sequencing. We detected three cases (16.7%) with the p53 gene mutations showing only the mutant alleles; the high incidence in cases with loss of a whole chromosome 17 (two of three) contrasted with the low incidence in cases without abnormalities of chromosome 17 (one of 15). These cases containing the mutations of the p53 gene showed a poor prognosis. Although we analyzed a rather small series of patients, these findings suggest that the p53 gene mutations might be involved in the progression and prognosis of at least some cases of AML.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7654857     DOI: 10.1007/bf01699251

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  29 in total

1.  Frequent p53 gene mutations in blast crisis of chronic myelogenous leukemia, especially in myeloid crisis harboring loss of a chromosome 17p.

Authors:  H Nakai; S Misawa; J Toguchida; D W Yandell; K Ishizaki
Journal:  Cancer Res       Date:  1992-12-01       Impact factor: 12.701

2.  Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction.

Authors:  M Orita; Y Suzuki; T Sekiya; K Hayashi
Journal:  Genomics       Date:  1989-11       Impact factor: 5.736

3.  Alterations in the p53 gene and the clonal evolution of the blast crisis of chronic myelocytic leukemia.

Authors:  H Ahuja; M Bar-Eli; S H Advani; S Benchimol; M J Cline
Journal:  Proc Natl Acad Sci U S A       Date:  1989-09       Impact factor: 11.205

4.  Mutations of the P53 gene in acute myeloid leukaemia.

Authors:  P Fenaux; C Preudhomme; I Quiquandon; P Jonveaux; J L Laï; M Vanrumbeke; M H Loucheux-Lefebvre; F Bauters; R Berger; J P Kerckaert
Journal:  Br J Haematol       Date:  1992-02       Impact factor: 6.998

Review 5.  The p53 tumour suppressor gene.

Authors:  A J Levine; J Momand; C A Finlay
Journal:  Nature       Date:  1991-06-06       Impact factor: 49.962

6.  Wild-type p53 is a cell cycle checkpoint determinant following irradiation.

Authors:  S J Kuerbitz; B S Plunkett; W V Walsh; M B Kastan
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-15       Impact factor: 11.205

7.  P53 gene mutations in acute myelogenous leukaemia.

Authors:  G Hu; W Zhang; A B Deisseroth
Journal:  Br J Haematol       Date:  1992-08       Impact factor: 6.998

8.  Prognostic significance of loss of a chromosome 17p and p53 gene mutations in blast crisis of chronic myelogenous leukaemia.

Authors:  H Nakai; S Misawa; M Taniwaki; S Horiike; T Takashima; T Seriu; H Nakagawa; H Fujii; C Shimazaki; N Maruo
Journal:  Br J Haematol       Date:  1994-06       Impact factor: 6.998

9.  Modulation of activity of the promoter of the human MDR1 gene by Ras and p53.

Authors:  K V Chin; K Ueda; I Pastan; M M Gottesman
Journal:  Science       Date:  1992-01-24       Impact factor: 47.728

10.  Mutations of the p53 gene in adult T-cell leukemia.

Authors:  A Sakashita; T Hattori; C W Miller; H Suzushima; N Asou; K Takatsuki; H P Koeffler
Journal:  Blood       Date:  1992-01-15       Impact factor: 22.113

View more
  1 in total

1.  Acquired, nonrandom chromosomal abnormalities associated with the development of acute promyelocytic leukemia in transgenic mice.

Authors:  D B Zimonjic; J L Pollock; P Westervelt; N C Popescu; T J Ley
Journal:  Proc Natl Acad Sci U S A       Date:  2000-11-21       Impact factor: 11.205

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.